Skip to main content
Fig. 3 | BMC Complementary Medicine and Therapies

Fig. 3

From: Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling

Fig. 3

IL-6 effects on p-STAT3 (A) and IL-23 levels (B) in HepG2 cells. The cells were stimulated with IL-6 and the levels of total STAT3, p-STAT3 and IL-23 were measured after 24 h. Niclosamide (NICLO) effects on p-STAT3 (C) and IL-23 levels (D) in the presence of IL-6 in HepG2 cells. The cells were treated with niclosamide in the presence of IL-6. The levels of total STAT3, p-STAT3 and IL-23 were assessed after 24 h. Data are presented as means and standard deviations of three independent experiments, with each experiment conducted in triplicate. *p < 0.05, **p < 0.01 and ***p < 0.001 corresponds to significant difference as determined by one-way ANOVA and Bonferroni’s test, ns: difference statistically not significant

Back to article page